Total records: 8
Today, hundreds of millions of people live in pain and suffering and will eventually die. At the end result, this will lead degenerative conditions of aging. Research undertaken in 2004 and 2005 suggests that the stem cells in the adult body - which become less effective at their job of repair with age – could be rejuvenated, restored to action with the right biochemical cues. Furthermore, researchers already regularly manipulate the genes and biochemistry of stem cells taken from patients for use in trials of new therapies.
2011/3/17
Participation Price:
For more information about the price please call us tel:+421 944 263926
It is very worrying to encounter disturbing news / cases on clinical trials not following ethically to the compliance given. Though we always knew (few notes below):
- All medicines are subject to rigorous testing before they are approved by regulatory authorities (such as the US Food and Drug Administration).
- All clinical studies in pharmaceutical companies are conducted in compliance with international guidelines according to Good Clinical Practice (GCP) and must be approved by regulatory authorities and Ethics Committees or local Institutional Review Boards.
2011/2/21
Participation Price:
For more information about the price please call us tel:+421 944 263926
The market for therapeutic monoclonal antibodies is one of the most dynamic sectors within the pharmaceutical industry. Next generation antibodies are forecast to drive the market towards a high level innovation in early-stage discovery and several potential niche busters set to launch in the next 5 years. This will allow the large market to continue to record robust growth. This is an opportunity since MAb Market is strong and expected to GROW stronger.
2011/1/29
Participation Price:
For more information about the price please call us tel:+421 944 263926
In this current economy, most pharmaceutical companies are desperate for an efficient decision making tools that saves time and R&D cost. The usage of Pharmacometric and PKPD tools in bridging the drug discovery to enhance drug developments have been increasingly favourable in making decision at different phases of pharmaceutical R&D successful implementation.
Participants will be equipped with latest insights through practical case studies from the market leaders.
2011/1/24
Participation Price:
For more information about the price please call us tel:+421 944 263926
Registration or request for brochure (please contact us for any enquiry)
Director of the Max Planck Institute for Infection Biology in Berlin - quote: As a result of dominant media coverage of new epidemic threats such as swine influenza, other infection risks receive less public attention than they deserve. "We would like to bring to everybody's attention that the infectious diseases with the most severe consequences continue to be old acquaintances such as tuberculosis, HIV/AIDS, malaria and hepatitis C. About six million people worldwide die of these diseases every year. "We urgently need vaccines against these great epidemics!" .
2010/10/18
Participation Price:
For more information about the price please call us tel:+421 944 263926
The au courant trend is now ‘shared risk and opportunities for shared reward’. The shift in mindset driving this trend is subtle; to succeed, it implies if not an explicit partnership then an implicit compromise between parties such as small biotech and big pharma, and drug developer and payor. The ramifications of this shift, which will encompass every player in the biopharma drug development ecosystem, are already influencing dealmaking decisions.
2010/10/18
Participation Price:
For more information about the price please call us tel:+421 944 263926
The potential for pharmaceutical sales forces to leverage growth and development of the industry is phenomenal. Over the next few years, pharmaceutical companies will find it severely difficult to increase revenue, due to patent expiries and a lack of new blockbuster drugs coming out of their R&D pipelines. As a result, the industry must scrutinise closely how to increase the ROI of their sales teams. Companies are therefore back to basics, which means relying on the calibre and effectiveness of the sales force whilst applying innovative sales force strategies.
2010/9/30
Participation Price:
For more information about the price please call us tel:+421 944 263926
The challenging economic climate presents an opportunity for all pharmaceutical market leaders to develop more robust and cost efficient data management processes for clinical trials at a critical time for the future of the industry.
2010/5/3
Participation Price:
For more information about the price please call us tel:+421 944 263926